Israel on Vaccine Experimental Site Promising Data on Drastic Reduction of Infection
Israel is rapidly inoculating Pfizer’s new coronavirus vaccine, which makes it the largest laboratory in the real world for research on this vaccine. The results are coming out little by little.
More than half of Israel’s potential population, or about 3.5 million, has so far received the first or second dose of a double-dose Pfizer vaccine. There is a dramatic reduction in onset in the elderly with priority and those at high risk.
According to Elan Segal, a data scientist at the Weizmann Institute of Science, 53% of new infections, 39% of hospitalizations and severe illnesses between mid-January and February 6 in the group that completed the second vaccination. The conversion decreased by 31%.
In people under the age of 60 who were vaccinated late, new infections decreased by 20% over the same period. However, hospitalization increased by 15% and aggravation increased by 29%.
One of the notable points of vaccination in the country is the effectiveness of the vaccine in non-controlled clinical trials and at what point in time the governments are pursuing but not easily available herd immunity. It provides a database that can be used as a basis for consideration as to whether or not it may be possible.
You’ll find out more in the next two weeks. The research team will analyze the effectiveness of the vaccine in certain populations, including younger people, people with diabetes and cancer, and pregnant women. The number of data available in these patients will be at least 10 times higher than in clinical trials.”
Pfizer also observes Israeli vaccinations weekly and hopes that this will be useful around the world. Israel is a country with a small population, a universal health insurance system, the ability to collect advanced data, and a promise of rapid vaccination deployment, making it ideal for Pfizer’s research.
However, the company says it remains difficult to accurately predict when herd immunity acquisition will begin to become apparent. This is because there are many important variable factors such as how to take interpersonal distance and the so-called reproduction number of infections.
Even in Israel, which is at the forefront of the world with the spread of new corona vaccination, the number of infections has increased significantly, and expectations for an early exit from the corona epidemic are low. The country has taken a third nationwide strict movement restriction measure, but is struggling to control the spread of the infection. This is mainly due to the rapid spread of British mutant viruses.
However, the vaccine that Pfizer co-developed with Germany’s Biontech is also believed to be effective for the British version. “We have so far found that the effectiveness against the British type is no different than 90-95%,” said Heji Levi, director of the Israeli Ministry of Health. However, since the second vaccination has only started for a week, it is still too early to make a decision. “I can’t say anything at this stage,” he said of the South African mutant.
Israel paid a higher price than other countries to purchase Pfizer’s vaccine and started vaccination on December 19, last year. Four days later, four British-type infected individuals, allegedly highly contagious, were found. The vaccine prevents the onset of the disease in the elderly, while mutant strains of the virus currently account for about 80% of new infections in the country.
In a situation where vaccination and mutant epidemics are competing for the speed of expansion, Israel has started vaccination for people over the age of 60. In addition, inoculation plans for the remaining layers have begun in stages. Inoculations are electronically tracked and recorded on a case-by-case basis. It also covers whether the person was struck on his left or right arm and from which bottle the vaccine was taken.
Israeli experts are convinced that vaccination reduces the number of infected people more than restrictions, based on studies by diverse cities and age groups and analysis of pre-vaccination mobility restrictions. “As a result of comparative studies, we are confident that the reduction in infections is due to the effects of the vaccine,” said Segal of the Weizmann Institute of Science.
As 80% of older people complete their first or second vaccination, more complete studies could begin to come out as early as this week. “We expect the overall number of infected and severely ill people to decrease further,” said Barriser of Clarit.
A follow-up study of Israel’s largest coronavirus testing center, run by My Heritage, shows that the number of viruses “carried” by infected people in the most inoculated age groups has dropped significantly. According to Janib Erlich, the director of the center, it is less likely to be transmitted to others if infected after being vaccinated.
“These data are probably the clearest so far, and vaccination is thought to reduce the chances of subsequent transmission to others,” said Stephen Baral of Johns Hopkins University. ..
It is unclear whether Israel will continue to be one of the fastest vaccination paces in the world.
However, with the rapid spread of infection with mutant strains derived from the United Kingdom, speeding up inoculation is becoming more important. Mr. Segal of the Weizmann Institute of Science said that if the British-style rapid spread and rapid vaccination speed competition were to take place, the result would be “a situation in which the number of severely ill people remains high.” I expected.
The big question is whether the vaccine can eradicate the new corona epidemic.
According to Hebrew University professor Mycal Linearl, data from decades of the past suggest that the virus may become endemic, in certain seasons. The aggression can be significantly reduced in the case of the new corona, but this requires re-vaccination every three years. “The new coronavirus itself will not go away,” he concludes.